Psoriasis

Disease State Hub

Research Summaries

Psoriasis

Could Psoriasis Therapy Increase Herpes Zoster Risk?

03/23/2015

A new study evaluated the impact of certain combination medications used to treat psoriasis on the risk of herpes zoster manifestation.

03/23/2015

Research Summary

Research Summary

Biologic Switching in Psoriasis Improves Outcomes, Raises Infection Risk

01/01/2015

Kate Young

In a recent study, interclass switching of biologic agents in psoriasis was associated with faster and more durable disease control, particularly when transitioning to anti–IL-23p19 therapies. However, the...

01/01/2015

Psoriasis

Does Psoriasis Cause Hypertension?

10/17/2014

A new study examined the impact of psoriasis on blood pressure control and hypertension.

10/17/2014

Psoriasis

Hypercholesterolemia Associated with Greater Psoriasis Risk

12/28/2013

Hypercholesterolemia is linked to an elevated possibility of incident psoriasis, according to a new study.

12/28/2013

Research Summaries

FDA Approval

FDA Approval

Icotyde (icotrokinra) Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis

03/19/2026

Anthony Calabro, MA

The FDA has approved icotrokinra, an oral interleukin-23 receptor antagonist, for patients aged 12 years and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or...

03/19/2026

ACC.25 Conference Coverage

Pair of hands holding a GLP-1 injector pen

ACC.25 Conference Coverage

GLP-1RA Use Associated With Lower Cardiovascular Event Risk in Patients With Psoriasis

04/07/2025

Miranda Manier, BA

A study presented at the American College of Cardiology's 74th Annual Scientific Session found that GLP-1RA use in patients with psoriasis was linked to a lower incidence of major adverse cardiovascular...

04/07/2025

Research Summary

Research Summary

Efficacy and Safety of Apremilast in Pediatric Patients With Moderate-to-Severe Plaque Psoriasis

02/05/2025

Miranda Manier, BA

A phase 3 trial evaluating apremilast in children and adolescents with moderate-to-severe plaque psoriasis showed improvements in disease severity compared with placebo over 16 weeks.

02/05/2025

Research Summary

Person with plaque psoriasis on back of neck

Research Summary

Long-Term Efficacy and Safety of Deucravacitinib in Moderate-to-Severe Plaque Psoriasis

01/13/2025

Miranda Manier, BA

A recent phase 3b long-term extension study assessed the safety and efficacy of deucravacitinib over 2 years in patients with moderate-to-severe plaque psoriasis.

01/13/2025

FDA ALERT

FDA ALERT

FDA Approves Interchangeable Biosimilar for Psoriatic Arthritis, Other Inflammatory Conditions

11/30/2023

Anthony Calabro, MA

The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.

11/30/2023

April 2026

Current Issue

April 2026